Acorda Therapeutics Inc

NASDAQ ACORQ

Data sourced from iex and EODHD
Download Data

Acorda Therapeutics Inc Return on Net Assets (RONA) 1 year YoY Change (%) for the quarter ending March 31, 2024: 807.91%

Acorda Therapeutics Inc Return on Net Assets (RONA) 1 year YoY Change (%) is 807.91% for the quarter ending March 31, 2024. Return on net assets measures the profitability of a company relative to its net assets, which include total non-current assets and working capital. It is calculated by dividing the net income by the sum of total non-current assets and working capital. This ratio indicates the return generated for each unit of net asset investment made by the company. A higher return on net assets suggests better profitability and efficient utilization of the company's asset base. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Acorda Therapeutics Inc Return on Net Assets (RONA) for the quarter ending March 31, 2023 was -4.12%.
NASDAQ: ACORQ

Acorda Therapeutics Inc

CEO -
IPO Date Feb. 10, 2006
Location United States
Headquarters 2 Blue Hill Plaza, Pearl River, NY, United States, 10965
Employees 102
Sector Healthcare
Industry Drug manufacturers - specialty & generic
Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

StockViz Staff

September 19, 2024

Any question? Send us an email